Relevance of leukemic stem cells in acute myeloid leukemia: Heterogeneity and influence on disease monitoring, prognosis and treatment design

Expert Review of Hematology

Volumn 7, Issue 6, 2014, Pages 791-805

  Wouters, Rolf ^a   Cucchi, David ^a   Kaspers, Gertjan J L ^a   Schuurhuis, Gerrit Jan ^a   Cloos, Jacqueline ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Clonal shifts; Leukemic stem cells; Minimal residual disease; Targeted therapy

Indexed keywords

ALDEHYDE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER STEM CELL; CELL COUNT; ENZYME ACTIVITY; FLOW CYTOMETRY; FOLLOW UP; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA RELAPSE; LIGHT SCATTER CELL; MINIMAL RESIDUAL DISEASE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PROGNOSIS;

ANIMALS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; PROGNOSIS;

EID: 84911456464     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.959921     Document Type: Review

References (111)

1. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol 2012;96(2):153-63
2. Balgobind B V, Hollink IHIM, Arentsen-Peters STCJM, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011;96(10):1478-87
3. Marcucci G, Mrózek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011;117(4):1121-9
4. Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 2014; 28(7):1396-406
5. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89(1):97-108
6. Bacher U, Kern W, Schnittger S, et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 2005;90(11): 1502-10
7. Kaspers GJL. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 2012;12(3):405-13
8. Grimwade D. The changing paradigm of prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2012;25(4):419-25
9. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012; 120(16):3187-205
10. Skalska-Sadowska J, Wachowiak J, Zaja?c-Spychała O, et al. Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005-2011-experience of the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). Contemp Oncol (Poznań, Poland) 2014;18(1):48-53
11. Kaspers GJL, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013;31(5): 599-607
12. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:43-8
13. Bachas C, Schuurhuis GJ, Reinhardt D, et al. Clinical relevance of molecular aberrations in paediatric Acute Myeloid Leukaemia at first relapse. Br J Haematol 2014; 166(6):902-10
14. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006; 20(7):1217-20
15. Bachas C, Schuurhuis GJ, Hollink IHIM, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010;116(15):2752-8
16. Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels. Ann Hematol 2014;93(7): 1149-57
17. Yin JAL, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120(14): 2826-35
18. Jain P, Kantarjian H, Patel K, et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 2014;55(6):1337-44
19. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120(8):1581-8
20. Feller N, van der Velden VHJ, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129
21. Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia 2014; 28(5):1131
22. Terwijn M, Kelder A, Snel AN, et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol 2012;34(4):432-41
23. Van der Velden VHJ, van der Sluijs-Geling A, Gibson BES, et al. Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24(9):1599-606
24. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006;24(22):3686-92
25. Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE 2013; 8(11):e78897
26. Hokland P, Ommen HB, Nyvold CG, Roug AS. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission-methodologies in relation to their clinical situation. Br J Haematol 2012; 158(5):569-80
27. Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a "moving target" for detection of residual disease. Cytometry B Clin Cytom 2014;86(1):3-14
28. Bachas C, Schuurhuis GJ, Assaraf YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012; 26(6):1313-20
29. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010; 2(17):17ra9
30. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12(11):767-75
31. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9(10):579-90
32. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010;28(3): 275-80
33. Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60(16):4403-11
34. Van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11(18):6520-7
35. Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 2014;In Press
36. Van der Pol MA, Feller N, Roseboom M, et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003;88(9):983-93
37. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 (-) fraction. Blood 2010;115(10):1976-84
38. De Jonge-Peeters SDPWM, Kuipers F, de Vries EGE, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62(3):214-26
39. Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98(4):1166-73
40. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 2001;97(12): 3882-9
41. Moshaver B, van Rhenen A, Kelder A, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008;26(12): 3059-67
42. Smith C, Gasparetto M, Humphries K, et al. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci 2014; 1310(1):58-68
43. Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119(15):3571-7
44. Miraki-Moud F, Anjos-Afonso F, Hodby KA, et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci USA 2013;110(33):13576-81
45. Feller N, van der Velden VHJ, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129
46. Van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21(8):1700-7
47. Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev 2011;25(2):75-81
48. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17(3):313-19
49. Hoang VT, Hoffmann I, Borowski K, et al. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia. Methods Mol Biol 2013;1035: 217-30
50. Witte K-E, Ahlers J, Schafer I, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol 2011;28(2):91-9
51. Ran D, Schubert M, Pietsch L, et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009; 37(12):1423-34
52. Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One 2013;8(11):e78897
53. Cheung AMS, Wan TSK, Leung JCK, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007;21(7):1423-30
54. Roshal M, Chien S, Othus M, et al. The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia. Leukemia 2013;27(3):728-31
55. HOVON. Available from: www.hovon.nl
56. Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31(31):3889-97
57. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150(2):264-78
58. Woll PS, Kjallquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014;25(6):794-808
59. Radojkovic M, Tosic N, Colovic N, et al. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia. Ann Clin Lab Sci 2012;42(2):186-90
60. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481(7382):506-10
61. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene 2013;32(2): 135-40
62. Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2014;9(6):e93353
63. Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;57(2): 204-9
64. De Leeuw DC, Denkers F, Olthof MC, et al. Attenuation of microRNA-126 expression that drives CD34+38-stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014;74(7): 2094-105
65. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25(3):379-92
66. Groen RWJ, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120(3): e9-e16
67. Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest 2013;93(9): 970-82
68. Schuringa JJ, Schepers H. Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells. Methods Mol Biol 2009;538:287-300
69. Mardiros A, Brown CE, Budde LE, et al. Acute myeloid leukemia therapeutics: CARs in the driver's seat. Oncoimmunology 2013; 2(12):e27214
70. Goldmacher VS, Kovtun Y V. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2011;2(3):397-416
71. Van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11(18):6520-7
72. Wang L, Gao L, Xu S, et al. FISH+CD34 +CD38-cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome. J Hematol Oncol 2013;6(1):85
73. Plesa A, Elhamri M, Clapisson G, et al. Higher percentage of CD34(+)CD38(-) cells detected by multi-parameter flow cytometry from leukapheresis products predict unsustained complete remission in AML. Leuk Lymphoma 2014. [Epub ahead of print]
74. Gentles AJ, Plevritis SK, Page P, et al. Association of a Leukemic Stem Cell Gene in Acute Myeloid Leukemia. JAMA 2010; 304(24):2706-15
75. Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011;96(12):1792-8
76. Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119(15):3571-7
77. Bartholdy B, Christopeit M, Will B, et al. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest 2014;124(3): 1158-67
78. De Leeuw DC, Denkers F, Olthof MC, et al. Attenuation of microRNA-126 expression that drives CD34+38-stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014;74(7): 2094-105
79. Metzeler KH, Maharry K, Kohlschmidt J, et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013;27(10):2023-31
80. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010;16(8): 903-8
81. Thol F, Winschel C, Sonntag A-K, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Ann Hematol 2013;92(3):315-23
82. Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood 2013;121(12):2289-300
83. Heidel FH, Bullinger L, Arreba-Tutusaus P, et al. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med 2013;210(1):15-22
84. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120(6):1290-8
85. Wang L, Gao L, Xu S, et al. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). Ann Hematol 2014;93(10): 1685-94
86. Hwang K, Park C-J, Jang S, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol 2012;91(10):1541-6
87. Walter RB, Laszlo GS, Lionberger JM, et al. Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia 2014;doi; 10.1038/leu.2014.107. [Epub ahead of print]
88. Schwemmlein M, Peipp M, Barbin K, et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006;133(2):141-51
89. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009;5(1):31-42
90. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12(10): 1167-74
91. Noordhuis P, Terwijn M, Rutten A, et al. Targeting of CLEC12A in acute myeloid leukemia by antibody-drug-conjugates and bispecific CLL-1xCD3 BiTE antibody. Blood 2010. 116([ASH Annual Meeting Abstracts 2890
92. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138(2):286-99
93. Theocharides APA, Jin L, Cheng P-Y, et al. Disruption of SIRPa signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012;209(10):1883-99
94. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
95. Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013;27(4):964-7
96. Al Hussaini M, Ritchey J, Rettig M, et al. Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs®). Blood 2013. 122(21), ASH Annual Meeting Abstracts
97. Zhao X, Singh S, Pardoux C, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010; 95(1):71-8
98. Askmyr M, Agerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013;121(18):3709-13
99. Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol 2013;98(6):627-33
100. Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med 2013;5(181):181ra52
101. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013;110(50):20224-9
102. Zhang H, Mi JQ, Fang H, et al. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci USA 2013; 110(14):5606-11
103. Weidenaar AC, Ter Elst A, Kampen KR, et al. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584. Mol Cancer Res 2013;11(4):339-48
104. Herrmann H, Blatt K, Shi J, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012;3(12): 1588-99
105. Beurlet S, Omidvar N, Gorombei P, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood 2013;122(16): 2864-76
106. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013;12(3):329-41
107. Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 2013; 122(11):1900-13
108. Roberts KG, Smith AM, McDougall F, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010;70(13):5438-47
109. Wang Y, Liu Y, Malek SN, et al. Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011;8(4):399-411
110. Su YC, Li SC, Wu YC, et al. Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia. Evid Based Complement Alternat Med 2013;2013:547430
111. Wu EJ, Goussetis DJ, Beauchamp E, et al. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Cancer Biol Ther 2014;15(4): 473-8